January #98 : Publisher's Letter - by Brad Peebles

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

10 Ways to End AIDS (in 10 years)

Happy New You

Political Science

"Prevention" for Positives

Habitats for HIVers

On the Job

Going Under Cover

All the Right Places

2024: AIDS Cured, ex-PWAs Ignored

Trouble Indemnity


Show & Gel

Healthful Humor

Living on Hope


High Resolution: New Year’s Creeds

2004: What’s In, What’s Out?


When Your CD4s Count

New Med on the Shelf

Quick Study: Virus in Vaginas

Strike a Pose

Chicago Hope?

Quick Study: Hep C

Watch Your Mouth


CMV Drug Does Double Duty

Bed Head

Unreality TV


Publisher's Letter

Amazing Race

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

January 2004

Publisher's Letter

by Brad Peebles

Last April, when my viral load began to rise, I switched from a four-drug boosted-protease combo to something the federal treatment guidelines say “Should Not Be Offered at Any Time”—the old, discredited, somewhat disparaged and poorly understood cancer drug hydroxyurea (HU). My doctor, Paul Bellman, and I paired it with ddI—and nothing else.

I really just wanted to go off meds for a while. But after three treatment breaks over the last six years, Paul persuaded me to try something different. Each break got longer, and we weren’t sure what would happen with the next one. So he mentioned HU as a possibility. He was excited about a very small study (of 20 HIVers) comparing structured treatment interruptions (STIs) between HIVers who took HU as part of their treatment and those who did not. The HU group fared better when they went off their meds. And since I’m always bugging Paul about new approaches to treatment, he thought I might be open to trying something unusual. Enter HU.

We had a long talk about the potential side effects, which can be nasty. These and the lack of conclusive evidence about the drug’s benefits are why the guidelines give it a thumbs-down. HU targets cells, especially CD4s, and stops them from reproducing. If they can’t reproduce, HIV can’t reproduce. And because HU doesn’t target the virus directly, you don’t develop resistance to it. The catch is, your CD4 count doesn’t necessarily rise and may even drop, and HU can knock out other good cells too, causing anemia or neutropenia. So it’s not for everyone. Still, feeling experimental and curious—but very skeptical—I decided to go for it.

That was seven months ago, and we haven’t ditched it yet. I don’t know what to tell you about the results. Whether or not it is “working” depends on what you think the goal of treatment should be. I’m not undetectable, and my CD4 count isn’t very high. But I’m also not sick. Reviewing my most recent lab results—a CD4 count of 244 and a viral load of 44,000 copies—Paul apologized after calling them “mediocre.” But they are, so I didn’t mind the word he’d chosen. I told him, “Numbers, mediocre. Clinical health, excellent.” I wanted to make sure he sees as strong a distinction between the two as I do. They are not the same thing.

That’s not to say that I don’t consider my labwork when making treatment decisions—just that I don’t think numbers define health or success. They are simply one of many inputs, not the ultimate goal. For example, when I’m on meds and my viral load gets to 5,000 or 10,000, that is a trigger to take action. But off meds or on a combo-lite, I’m perfectly happy to have a viral load of 44,000. In the nearly 10 years that I’ve been making treatment decisions, I’ve frequently gone against the grain—if not always against the guidelines. I’ve taken some risks. I feel strongly that this may be the most important contribution to my relative good health today. Of course, risk-taking can backfire and be destructive. It’s what got many of us here (infected with HIV) in the first place. But there’s a big difference between informed, educated risk-taking and all the other crazy things we do.

It helps to have an experienced, open-minded doctor like Paul, who’s been my partner and guide through it all. Not that we always agree. In fact, after my number-vs.-health wisecrack, we argued about how no studies are done with clinical endpoints anymore—they are all geared towards surrogate markers like CD4 count and “undetectable.” Clinical endpoint studies are much more expensive and might even take decades. But on this unorthodox HU/ddI regimen, I am my own little study—with my clinical health, not my numbers alone, as the end point, and the only point. I’ll keep you posted on the results.

-- Brad Peebles
e-mail: BradP@poz.com

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.